Phase I clinical trial of human vascular endothelial growth factor receptor 1 peptide vaccines for patients with metastatic renal cell carcinoma.
Phase I clinical trial of human vascular endothelial growth factor receptor 1 peptide vaccines for patients with metastatic renal cell carcinoma.
复制标题
DOI：
10.1038/bjc.2013.90
复制
发表时间：
2013-04-02
影响因子：
8.8
通讯作者：
Uemura, H.
中科院分区：
文献类型：
--
作者：
Yoshimura, K.;Minami, T.;Nozawa, M.;Uemura, H.
关键词：
众所周知，肾细胞癌（RCC）是最具免疫应答性的癌症之一。尽管在RCC中缺乏明确的抗原阻碍了更特异性疫苗的开发，但30多年来，关于疫苗治疗的研究一直是RCC治疗的特别兴趣。为了评估血管内皮生长因子受体1 （VEGFR1）肽疫苗接种的安全性及其临床结果，收集了18例接受VEGFR1疫苗治疗的转移性RCC （mRCC）患者的数据。进行了毒性评估。临床结果包括采用CT扫描、磁共振成像或x线检查，按照WHO实体瘤反应评价标准进行评估。没有患者显示出任何3级或以上的毒性。18例患者中，2例患者在治疗过程中出现部分缓解。8例患者病情稳定超过5个月，中位病程16.5个月（4-32个月）。在本研究分析时，6例患者存活，中位随访时间为30个月（26-36个月）。这些结果表明VEGFR1肽疫苗是安全的，推荐用于mRCC患者的进一步试验。
It is well known that renal cell carcinoma (RCC) represents one of the most immune-responsive cancers. Although the lack of defined antigens in RCC has hindered more specific vaccine development, research regarding vaccination therapy has been of special interest for the treatment of RCC for more than 30 years. To evaluate the safety of the vascular endothelial growth factor receptor 1 (VEGFR1) peptide vaccination and its clinical outcomes, data from 18 metastatic RCC (mRCC) patients treated with VEGFR1 vaccine were collected. Toxicity assessments were performed. Clinical outcomes included assessment using CT scanning, magnetic resonance imaging or X-ray examination in accordance with the WHO Response Evaluation Criteria in Solid Tumors. No patient showed any toxicities of grade 3 or greater. Of the 18 patients, 2 patients showed a partial response during treatment. Stable disease for more than 5 months was observed in eight patients with a median duration of 16.5 months (4–32 months). At the time of the analysis in this study, six patients were alive with a median follow-up of 30 months (26–36 months). These results suggest that VEGFR1 peptide vaccine is safe and is recommended for further trials for patients with mRCC.
登录
查看更多内容
影响因子：
10.3
作者：
Correale, P;Walmsley, K;Tsang, KY
通讯作者：
Tsang, KY
影响因子：
11.5
作者：
Uemura, H;Fujimoto, K;Itoh, K
通讯作者：
Itoh, K
影响因子：
5.7
作者：
Miyazawa, Motoki;Ohsawa, Ryuji;Yamaue, Hiroki
通讯作者：
Yamaue, Hiroki
针对血管内皮生长因子受体FLK1的主动免疫抑制肿瘤血管生成和转移。
影响因子：
15.3
作者：
Li, Yiwen;Wang, Mei-Nai;Li, Hongli;King, Karen D;Bassi, Rajiv;Sun, Haijun;Santiago, Angel;Hooper, Andrea T;Bohlen, Peter;Hicklin, Daniel J
通讯作者：
Hicklin, Daniel J
影响因子：
6.4
作者：
Suzuki, N;Maeda, Y;Itoh, K
通讯作者：
Itoh, K